These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1255 related articles for article (PubMed ID: 18292929)

  • 1. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
    Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
    Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine acts through a novel extracellular receptor to inhibit granule exocytosis by natural killer cells.
    Williams BA; Manzer A; Blay J; Hoskin DW
    Biochem Biophys Res Commun; 1997 Feb; 231(2):264-9. PubMed ID: 9070261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-chloroadenosine stimulates granule exocytosis from mouse natural killer cells: evidence for signal transduction through a novel extracellular receptor.
    Williams BA; Blay J; Hoskin DW
    Exp Cell Res; 1997 May; 233(1):187-97. PubMed ID: 9184087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor.
    Miller JS; Cervenka T; Lund J; Okazaki IJ; Moss J
    J Immunol; 1999 Jun; 162(12):7376-82. PubMed ID: 10358189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
    Poggi A; Zocchi MR
    Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells.
    Hoskin DW; Butler JJ; Drapeau D; Haeryfar SM; Blay J
    Int J Cancer; 2002 May; 99(3):386-95. PubMed ID: 11992407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cell receptors as tools in cancer immunotherapy.
    Sentman CL; Barber MA; Barber A; Zhang T
    Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
    Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NKG2D ligands in tumor immunity.
    Nausch N; Cerwenka A
    Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression.
    Ghiringhelli F; Ménard C; Martin F; Zitvogel L
    Immunol Rev; 2006 Dec; 214():229-38. PubMed ID: 17100888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Chloroadenosine inhibits the MHC-unrestricted cytolytic activity of anti-CD3-activated killer cells: evidence for the involvement of a non-A1/A2 cell-surface adenosine receptor.
    Hoskin DW; Reynolds T; Blay J
    Cell Immunol; 1994 Nov; 159(1):85-93. PubMed ID: 7954843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling.
    Raskovalova T; Lokshin A; Huang X; Su Y; Mandic M; Zarour HM; Jackson EK; Gorelik E
    Cancer Res; 2007 Jun; 67(12):5949-56. PubMed ID: 17575165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
    Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
    Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate immune recognition and suppression of tumors.
    Hayakawa Y; Smyth MJ
    Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.
    Katou F; Ohtani H; Watanabe Y; Nakayama T; Yoshie O; Hashimoto K
    Cancer Res; 2007 Dec; 67(23):11195-201. PubMed ID: 18056444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells.
    Lokshin A; Raskovalova T; Huang X; Zacharia LC; Jackson EK; Gorelik E
    Cancer Res; 2006 Aug; 66(15):7758-65. PubMed ID: 16885379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.